ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment

Stock Information for Impact BioMedical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Impact BioMedical Inc.

Join ProPhase Labs' Exclusive Live Investor Webinar and Q&A Session on December 1
ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.
ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19
ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals
ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology
ProPhase Labs Engages RedChip Companies to Lead Investor Relations Efforts
ProPhase Labs to Present at the 2025 ThinkEquity Conference
ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.